Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000409

Drug Information
SynonymsClindamicina; AC1OFCJ7; CID3032758; Dalacin T Topical Solution; 7-Chloro-7-deoxylincomycin; NCGC00179636-01; HMS2089A05; Chlolincocin; AC1MHUOE; AC1OFCIP; 24620-78-8; 7-CDL; Clindamycine [French]; Prestwick3_000137; NINDS_000464; CID9812677; AC1OIBYN; Clinimycin; SMP2_000295; LS-187128; MLS001183714; CID7276016; Spectrum2_000885; KBio1_000464; BSPBio_002049; SPBio_000670; CID7048644; AC1OFCJ1; 58207-19-5; CID446598; KBioSS_000638; CID3034218; IDI1_000464; D00277; C18H33ClN2O5S; Dalacin C; Spectrum_000158; Clindamycin & VRC3375; Dalacin C Flavored Granules; SPBio_002153; ClindaDerm; AC1L1GLA; Dalacin C Phosphate; CID7048642; clindamycin; 7(S)-Chloro-7-deoxylincomycin; 16669-21-9; AC1O7ENS; Clindamycine [INN-French]; STOCK1N-31150; LS-98131; CID7048648; MolPort-002-964-479; Klimicin; DivK1c_000464; Chlorodeoxylincomycin; BPBio1_000236; STK177246; Cleocin; Prestwick0_000137; CID6604361; HSDB 3037; UNII-3U02EL437C; AC1MHX4G; MolPort-002-323-206; KBio2_005774; AC1OIBYJ; Clindamycin & Interleukin 12; Klindan 300; Clindamycinum [INN-Latin]; Clindamycinum; Cleocin T Gel; BSPBio_000214; Cleocin (TN); BIDD:GT0418; Zindaclin; CHEBI:3745; CID5702026; CID6602476; BRD-A23034328-003-03-4; Cleocin HCl; Clindamycin [USAN:BAN:INN]; AC1MHD7N; CLINDA & IL-12; Prestwick2_000137; Dalacine; DB01190; AC1L1EGQ; 7-Chlorolincomycin; ResiDerm A; EINECS 242-209-1; CLDM; CID7276018; Chlorlincocin; 21462-39-5 (mono-hydrochloride); Spectrum3_000355; AC1OFCIV; CID7048646; U 21251; CID7276014; AC1Q2V4O; KBio3_001269; AC1OIBYL; Prestwick1_000137; Clindamycine; CID2786; Sobelin; Clindamicina [INN-Spanish]; KBio2_003206; NCGC00178843-01; C06914; NCGC00016752-01; HMS2089N16; 13441-63-9; Spectrum4_000292; U-21,251; Chlorolincomycin; CID29029; CLY; Cleocin T Lotion; 24696-19-3; Clindamycin (USAN/INN); AC1MHE1M; AC1O7GED; CID3001928; SMR000677917; CAS-21462-39-5; Antirobe; U-21251; I06-0826; Spectrum5_001525; 7-Deoxy-7(S)-chlorolincomycin; KBioGR_000844; 18323-44-9; CID3000512; AC1L9JV8; CHEMBL187; Cleocin T Topical Solution; KBio2_000638; AC1NWAKO    
Trade NameDalacin; Clindacin; Cleocin; Evoclin    
CompanyPfizer Pharmaceuticals    
IndicationBacterial infectionsApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntibacterial Agents    
CAS NumberCAS 18323-44-9
PubChem Compound IDCID 5702026.    
PubChem Substance IDSID 11335639.    
SuperDrug ATC IDD10AF01;    
SuperDrug CAS ID018323449;    
Target50S ribosomal subunitBinder[2]
Ref 1How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. To Reference
Ref 2Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543